Transthyretin Amyloidosis Treatment Market By Product Type (ATTR-CM, ATTR-PN), By Therapy (Targeted Therapy, Supportive Therapy), By Disease Type (Hereditary Amyloidosis, Wild-type Amyloidosis, Other), By Distribution Channel (Hospitals Pharmacy, Retail Pharmacies, Other), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Published Date: Mar 2025 | Report ID: MI2259 | 210 Pages

Report Summary Table of Contents Segmentation FAQ Request Free Sample Report

Report Coverage:

By Product Type

  • ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
  • ATTR-PN (Transthyretin Amyloid Polyneuropathy)

By Therapy

  •  Targeted Therapy
  •  Supportive Therapy

By Disease Type

  • Hereditary Amyloidosis
  • Wild-type Amyloidosis
  • Other

By Distribution Channel

  • Hospitals Pharmacy
  • Retail Pharmacies
  • Other

By Region

North America

  • U.S
  • Canada

Europe

  • U.K.
  • France
  • Germany
  • Spain
  • Rest of Europe
  • Italy

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

List of Companies:

  • Alnylam Pharmaceuticals
  • Bridgebio Pharma
  • Pfizer
  • Ionis Pharmaceuticals
  • Astrazeneca
  • Alexion Pharmaceutical
  • Proliferan
  • Enobio Pharma
  • Moderna
  • Intellia Therapeutics
  • Regeneron Pharmaceuticals
  • SomaLogic
  • Prothena Corporation
  • Eidos Therapeutics
  • Corina Therapeutics

Maximize your value and knowledge with our 5 Reports-in-1 Bundle - over 40% off!

Our analysts are ready to help you immediately.

Request Bundle Pricing